These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 22913807)

  • 61. Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.
    Stättermayer AF; Strassl R; Maieron A; Rutter K; Stauber R; Strasser M; Beinhardt S; Datz C; Scherzer TM; Steindl-Munda P; Gschwantler M; Trauner M; Hofer H; Ferenci P
    Aliment Pharmacol Ther; 2014 Jan; 39(1):104-11. PubMed ID: 24205831
    [TBL] [Abstract][Full Text] [Related]  

  • 62. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.
    Mangia A; Thompson AJ; Santoro R; Piazzolla V; Tillmann HL; Patel K; Shianna KV; Mottola L; Petruzzellis D; Bacca D; Carretta V; Minerva N; Goldstein DB; McHutchison JG
    Gastroenterology; 2010 Sep; 139(3):821-7, 827.e1. PubMed ID: 20621700
    [TBL] [Abstract][Full Text] [Related]  

  • 63. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.
    Hayes CN; Kobayashi M; Akuta N; Suzuki F; Kumada H; Abe H; Miki D; Imamura M; Ochi H; Kamatani N; Nakamura Y; Chayama K
    Gut; 2011 Feb; 60(2):261-7. PubMed ID: 21068134
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.
    Pineda JA; Caruz A; Rivero A; Neukam K; Salas I; Camacho A; Palomares JC; Mira JA; Martínez A; Roldán C; de la Torre J; Macías J
    Clin Infect Dis; 2010 Oct; 51(7):788-95. PubMed ID: 20804372
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism.
    Del Campo JA; Ampuero J; Rojas L; Conde M; Rojas A; Maraver M; Millán R; García-Valdecasas M; García-Lozano JR; González-Escribano MF; Romero-Gómez M
    Aliment Pharmacol Ther; 2013 Jan; 37(1):74-80. PubMed ID: 23121166
    [TBL] [Abstract][Full Text] [Related]  

  • 66. IL28B gene polymorphisms and US liver fatty changes in patients who spontaneously cleared hepatitis C virus infection.
    Taliani G; Spaziante M; Biliotti E; Borro M; Palazzo D; Grieco S; Franchi C; Iaiani G; Furlan C; Gallinaro V; Simmaco M
    PLoS One; 2013; 8(8):e67301. PubMed ID: 23936294
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.
    Haj-Sheykholeslami A; Keshvari M; Sharafi H; Pouryasin A; Hemmati K; Mohammadzadehparjikolaei F
    World J Gastroenterol; 2015 Aug; 21(29):8935-42. PubMed ID: 26269684
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.
    Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Tangkijvanich P; Treeprasertsuk S; Thaimai P; Wasitthankasem R; Poovorawan Y; Komolmit P
    PLoS One; 2015; 10(9):e0137365. PubMed ID: 26339796
    [TBL] [Abstract][Full Text] [Related]  

  • 69. IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population.
    Cavalcante LN; Abe-Sandes K; Angelo AL; Machado TM; Lemaire DC; Mendes CM; Pinho JR; Malta F; Lyra LG; Lyra AC
    Liver Int; 2012 Mar; 32(3):476-86. PubMed ID: 22098416
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis.
    Sato M; Kondo M; Tateishi R; Fujiwara N; Kato N; Yoshida H; Taguri M; Koike K
    PLoS One; 2014; 9(3):e91822. PubMed ID: 24637774
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Interleukin-28B genetic variations and spontaneous clearance of hepatitis C antibody-positive blood donors in China.
    Liu Y; Ma H; Chen S; Wang J; Liu G; Xu M; Ke L; He M
    Transfusion; 2013 Oct; 53(10 Pt 2):2498-504. PubMed ID: 23782163
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Variation in genes encoding for interferon λ-3 and λ-4 in the prediction of HCV-1 treatment-induced viral clearance.
    Palmieri O; Ippolito AM; Margaglione M; Valvano MR; Gioffreda D; Fasano M; D'Andrea G; Corritore G; Milella M; Andriulli N; Morisco F; Giannitrapani L; Latiano A; Fontana R; Gatti P; Tundo P; Barone M; Cozzolongo R; Santantonio T; Andriulli A
    Liver Int; 2014 Oct; 34(9):1369-77. PubMed ID: 25283962
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5Δ32 mutation.
    Nattermann J; Timm J; Nischalke HD; Olbrich A; Michalk M; Tillmann HL; Berg T; Wedemeyer H; Tenckhoff H; Wiese M; Kullig U; Göbel U; Capka E; Schiefke I; Güthof W; Grüngreiff K; König I; Roggendorf M; Sauerbruch T; Spengler U;
    J Hepatol; 2011 Dec; 55(6):1201-6. PubMed ID: 21703201
    [TBL] [Abstract][Full Text] [Related]  

  • 74. No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance.
    Visco-Comandini U; Lapa D; Taibi C; Angeletti C; Capobianchi MR; Garbuglia AR
    Dig Liver Dis; 2014 Apr; 46(4):348-52. PubMed ID: 24387833
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection.
    Grebely J; Petoumenos K; Hellard M; Matthews GV; Suppiah V; Applegate T; Yeung B; Marks P; Rawlinson W; Lloyd AR; Booth D; Kaldor JM; George J; Dore GJ;
    Hepatology; 2010 Oct; 52(4):1216-24. PubMed ID: 20803561
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The influence of single and combined IL28B polymorphisms on response to treatment of chronic hepatitis C.
    Lazarevic I; Djordjevic J; Cupic M; Karalic D; Delic D; Svirtlih N; Simonovic J; Svorcan P; Milic N; Jovanovic T
    J Clin Virol; 2013 Sep; 58(1):254-7. PubMed ID: 23831131
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals.
    Sharafi H; Pouryasin A; Alavian SM; Behnava B; Keshvari M; Salimi S; Mehrnoush L; Fatemi A
    Hepat Mon; 2012 Dec; 12(12):e8387. PubMed ID: 23550102
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Association between IL28B polymorphisms and spontaneous clearance of hepatitis B virus infection.
    Kim SU; Song KJ; Chang HY; Shin EC; Park JY; Kim DY; Han KH; Chon CY; Ahn SH
    PLoS One; 2013; 8(7):e69166. PubMed ID: 23874902
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effects of polymorphisms in interferon λ 3 (interleukin 28B) on sustained virologic response to therapy in patients with chronic hepatitis D virus infection.
    Yilmaz E; Baran B; Soyer OM; Onel M; Onel D; Ormeci AC; Gokturk S; Evirgen S; Akyuz F; Demir K; Besisik F; Kaymakoglu S; Karaca C
    Clin Gastroenterol Hepatol; 2014 Oct; 12(10):1753-8. PubMed ID: 24582569
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Simultaneous genotyping of rs12979860 and rs8099917 variants near the IL28B locus associated with HCV clearance and treatment response.
    Melis R; Fauron C; McMillin G; Lyon E; Shirts B; Hubley LM; Slev PR
    J Mol Diagn; 2011 Jul; 13(4):446-51. PubMed ID: 21704279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.